Introduction:The treatment of cutaneous aging with fractional non-ablative lasers has been intensely studied in the last few years, yet the number of publications describing specific equipments is limited.
Objective: To describe patient and dermatologist satisfaction after treatment with the Lux 1540®laser.
Methods: Retrospective study of patients (n=16) who have undergone facial rejuvenation therapy with Lux 1540® laser. Photographic assessments were performed by a dermatologist not involved in the treatments. Patient satisfaction was analyzed before treatment and after three sessions. The study variables were spots, sagging, wrinkles, enlarged pores, telangiectasias, and general satisfaction.
Results: In the dermatologist''''''''s evaluation, good or excellent improvement was found in the majority of the patients, for all studied variables. Regarding the improvement in the patients'''''''' general appearance, 82% were rated good or excellent. Regarding patients'''''''' opinions, 63% expressed good to excellent general satisfaction.
Conclusions: Treating cutaneous aging with Lux 1540® laser yields satisfactory results and maybe a good option for patients that do not want or cannot undergo more aggressive treatments.

Keywords: LASERS, SKIN AGING, LASER THERAPY

Introduction: Currently there is a growing demand for non-invasive therapies aimed at treating facial aging. Non-ablative fractional lasers lead to excellent outcomes, with reduced side effects. Objective: To evaluate the facial rejuvenation achieved by 1,340nm non-ablative fractional laser using a single pass at high energy versus three passes at medium energy, through a prospective comparative study. Methods: Twenty patients with facial aging were treated with 2 or 3 laser sessions with 4-week intervals. The right hemiface was treated with three passes of 1,340nm non-ablative fractional laser at a fluence of 90 mJ, pulse duration of 5ms and 100 mtz/ cm2. The left hemiface was treated with a single pass of the same laser at a fluence of 120 mJ, pulse duration of 5ms and 100 mtz/cm2. The evaluated variables were spots, wrinkles, porphyrins and overall appearance. Results: The patients (n = 20) were evaluated during 6 to 24 months. The photographic evaluations demonstrated a significant improvement of the spots on the right hand side and wrinkles on the right and left hand sides. Eighteen of the 20 patients reported satisfaction with the treatment. Conclusion: 1,340nm non-ablative fractional laser was proven as a modern, safe and effective alternative for facial rejuvenation. For spots, the triple passes at medium energy protocol led to a superior response. However, regarding wrinkles there was no difference between the single pass at high energy and triple pass at medium energy protocols.

Keywords: LASER; REJUVENATION; FACIAL AGING; FACE

INTRODUCTION: The chest is a photoexposed area that shows effects of photodamage. Microneedling is a safe option for the rejuvenation of this area, also leading to improvement in dyschromias.
OBJECTIVE: To evaluate histologic cutaneous response after three monthly sessions of microneedling for the treatment of dyschromias on the chest.
METHODS: Three monthly sessions of microneedling, with 1.5mm length needles were performed, as well as skin biopsies before and 90 days after commencement of the study. Histologic samples were evaluated with H&E and Fontana-Masson stains. Melanin content was measured based on dermal clusters.
RESULTS: Six patients between 38 and 67 years of age, phototypes II-III, Glogau scale II-IV were included. A positive correlation was observed between the time and dermal content of melanin (p=0.029): three sessions of microneedling reduced this content on D90 compared to the beginning (6.4 ± 1.7 MC on D0 versus 3.1 ± 0.4 on D90, p = 0.05). Three patients reported global skin improvement on D90.
CONCLUSIONS: The proposed mechanism of microneedling to promote lightening includes fibroblast proliferation and neocollagenesis in the upper dermis. This is the first study to evaluate the histology of the findings associated to lightening of the chest due to microneedling.

Keywords: Histology; Melanins; Needles; Thorax

The number of evidence supporting the existence of a “gut-skin axis” correlation has grown. There is also a suggestion that the intestinal microbiota modulation may play an essential role in dermatological diseases. Studies have shown that probiotics' oral use can have beneficial effects in treating skin diseases with inflammatory origins such as atopic dermatitis, acne, and others. However, there is no standardization as to what doses or species should be used for the treatments. We provide an overview of the use of probiotics as a treatment for dermatological diseases, focusing on mechanisms of action and clinical results reported in the literature.

Keywords: Probiotics; Skin; Skin diseases

In recent years, there has been an increasing trend toward the search for nature-friendly cosmetics without chemical or synthetic ingredients, thus boosting sales of products within this market niche. Currently, the term clean beauty refers to products that do not contain ingredients with unknown impacts on our bodies or that are potentially harmful to the environment. However, the definition of green beauty products, as well as vegan, natural, or organic products, is not regulated by ANVISA. Therefore, this study aimed to review these definitions to facilitate the medical understanding of the subject.

Keywords: Beauty; Cosmetics; Beauty products; Green chemistry Technology

INTRODUCTION: Advanced glycation end products (AGEs) are stable compounds formed by nonenzymatic reactions between amino groups of biomacromolecules and carbonyl groups of reducing sugars. AGEs are known to play a role in various diseases such as diabetes, cardiovascular diseases, and neurodegenerative disorders, as well as contributing to premature skin aging. Decarboxy carcinine HCl, a stable analogue of carnosine, has demonstrated potential in reducing the effects of glycation.
OBJECTIVE: To evaluate the effects of oral supplementation with Glycoxil^®, a patented decarboxy carcinine HCl molecule, on signs of skin aging in participants with mature skin.
METHODS: This randomized, double-blind, placebo-controlled study involved 30 participants aged 30-50 years, with skin phototypes I to IV and clinical signs of skin aging (e.g., rhytids). Participants were divided into two groups: one received Glycoxil^® 300 mg daily for 90 days, while the other received a placebo. Standardized skincare products were provided, and participants underwent evaluations using Visia^® and Focco^® imaging systems at baseline (T0), 45 days (T45), and 90 days (T90). Statistical analysis was conducted using RStudio, with ANOVA and Wilcoxon tests. Significance was set at p<0.05.
RESULTS: Of the 30 participants, 18 were analyzed with Focco^® and 22 with Visia^®. Objective evaluations showed no statistical differences between groups in rhytid improvement at T0, T45, or T90. However, slight improvements were observed in the treatment group at T45 and T90. Blinded dermatologists noted improvements in hydration, firmness, and texture in both groups, with some participants in the treatment group reporting "improved" or "much improved" appearance. No adverse effects were reported.
CONCLUSIONS: Although no statistically significant differences were found between the groups, the findings suggest that Glycoxil^® may contribute to minor improvements in skin-aging signs, corroborating existing literature on anti-glycation strategies. Further studies with larger sample sizes, extended follow-up periods, and advanced analytical methods are recommended to confirm these preliminary results.

Keywords: Glycation End Products, Advanced; Antiglycation Agents; Maillard Reaction.